Delving into the Latest Updates on Kaplan Hospital with Synapse

概览

关联

1

项与 Kaplan Hospital 相关的药物

NPS-846

靶点

GRI

作用机制

GRI 拮抗剂

在研机构-

原研机构

NPS Pharmaceuticals, Inc.

在研适应症-

非在研适应症

脑水肿 [+3]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Kaplan Hospital 相关的临床结果

登录后查看更多信息

0 项与 Kaplan Hospital 相关的专利（医药）

登录后查看更多信息

4

项与 Kaplan Hospital 相关的文献（医药）

2024-06-01·Journal of Clinical Oncology

Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.

作者: Evron, Ella ; Martinez-Bueno, Alejandro ; García-Sáenz, Jose A. ; Bischof, Georg Friedrich ; de Miguel, Maria J. ; Quinn, David I. ; Unni, Nisha ; Reid, Sonya A. ; Brufsky, Adam ; Solit, David B. ; Saura, Cristina ; Eli, Lisa DeFazio ; Hurvitz, Sara A. ; Bebchuk, Judith D. ; Mahalingam, Devalingam ; Wildiers, Hans ; Jhaveri, Komal L. ; De La Fouchardiere, Christelle ; Guerrero, Angel ; Bose, Ron

1094 Background: Genomic analyses of the SUMMIT metastatic breast cancer (mBC) cohorts suggested that resistance to neratinib (N) occurred primarily via acquisition of additional HER2alterations [Smyth et al. Cancer Discovery 2020]; this finding was independently confirmed in the MutHER clinical trial [Ma et al. Clin Cancer Res 2022]. Addition of trastuzumab (T) to N + fulvestrant (F) in HR+, HER2-negative, HER2-mutant mBC revealed increased efficacy compared to N+F [Jhaveri et al. Ann Oncol 2023]. Here, we report final data from SUMMIT evaluating whether the addition of T to N could improve outcomes in patients (pts) with HER2-mutant, triple-negative mBC (representing up to 3% of triple-negative mBCs) and performed next-generation sequencing (NGS) of serial biopsies to evaluate mechanisms of sensitivity and resistance. Methods: Pts with HER2-mutant triple-negative mBC received N (original SUMMIT cohort) or N+T (in the subsequent cohort): oral N 240 mg/d, i.v. T 8 mg/kg initially followed by 6 mg/kg q3w. Loperamide prophylaxis was mandatory during the first two cycles. Efficacy endpoints: confirmed objective response rate and clinical benefit rate (RECIST v1.1 or modified PERCIST); duration of response; progression-free survival. Retrospective central NGS was performed by MSK-IMPACT (tissue) or MSK-ACCESS (plasma). Results: 10 and 17 pts with triple-negative mBC were enrolled in the N and the N+T cohorts, respectively. Median no. of prior systemic regimens for metastatic disease was 2.5 (range 0–6) for the N and 2 (range 0–7) for the N+T cohort. Efficacy findings are summarized (Table). Diarrhea was the most commonly reported adverse event (N 80% any grade; 20% grade 3; N+T 100% any grade; 18% grade 3; no grade 4/5 or permanent discontinuations in either cohort). Correlation of efficacy to central NGS analysis is ongoing and will be reported. Conclusions: Treatment with either N and/or N+T yielded promising clinical efficacy and has been included in recent NCCN guidelines for HER2-mutant, triple-negative mBC. Molecular mechanisms of intrinsic or acquired sensitivity/resistance per genomic analysis will be reported. Clinical trial information: NCT01953926 . [Table: see text]

1999-04-01·Cardiovascular Surgery

Estrogen and Progesterone Receptors in Normal and Varicose Saphenous Veins

作者: Rose, S. S. ; Ben-Hur, H. ; Mashiah, A. ; Thole, H. H. ; Schwarz, H. ; Berman, V. ; Pasik, S.

The presence of estrogen and progesterone receptors was investigated in the walls of normal and varicose veins. Cryostat sections from the saphenous veins of 29 normal individuals, and varicose and normal vein segments of 32 patients with varicose veins, were stained with anti-estrogen or anti-progesterone receptor antibodies. Nuclear stain intensity was scored by three independent observers. Receptors to both hormones were detected in the nuclear regions of the intima and media in females and males. In the adventitia, estrogen and the progesterone receptors were found only in nuclei of the vasa vasorum. Estrogen receptor levels were lower in non-varicose segments of varicose veins compared with normal veins. In varicose segments, estrogen receptors were more abundant than in the non-varicose parts of the same vein, especially in females. Similarly, progesterone receptor levels in the non-varicose portions were higher in females. These gender differences may be related to hormonal action. However, these differences may also be age related. These findings may be related to the involvement of sex-hormones in varicosis, by mechanisms as yet unknown.

1997-01-01·Gynecologic and Obstetric Investigation4区 · 医学

Computed Sonography: Requiem to Echogenicity Assessment?

4区 · 医学

Article

作者: Streltzhoff, J ; Blickstein, I ; Gurewitsch, E ; Smith-Levitin, M ; Goldman, R D ; Chervenak, F A

We studied the influence of changes in gain settings, log compression, persistence, preprocessing, and postprocessing on image density in the fetal liver model. Each parameter was studied while the others were held constant. The image density was objectively measured by electrooptical transmission densitometry using a transparent film output. Neither the persistence nor the preprocessing levels significantly changed image density. Postprocessing of sonographic images produced significant differences (p < 0.02) in mean image density of most of the various postprocessing curves and is a serious confounder of tissue echogenicity assessment. The data reconfirmed that there is a linear relationship (r = -0.94 to -0.997) between image density and gain setting. However, each log compression setting significantly changed (p < 0.0000001) this relationship, obviating possible image density calibration. Our data suggest that manipulation of image parameters by computed sonographic technology obviates accurate echogenicity assessment.

100 项与 Kaplan Hospital 相关的药物交易

登录后查看更多信息

100 项与 Kaplan Hospital 相关的转化医学

登录后查看更多信息